Dermozone eyes $42mn revenue from herbal skincare products

Indo-Dermozone Herbal, makers of Indonesia-based herbal skin care products Dermozone, today said its target would be to reach 3-4 million households in India for its soon to be launched herbal skincare products with revenue target of $42 million over the next three years.

“We are launching our herbal skin care products Dermozone in India soon and targets revenue of $42 million over the next three years,” a company’s statement issued here said.

The company would also be looking at establishing India as a hub for managing all the technology, sales and customer support to other countries as well, it said.

Dermozone had recently announced its entry into the Indian market by setting up an office in Bengaluru in the name of Indo-Dermozone Herbal Pvt Ltd.

The company also announced the appointment of Manjunatha K G as the Chief Operation Officer of Indo-Dermozone Herbal, who would lead and oversee the Indian operations.

Dermozone is globally recognised for its wide range of herbal skin care products especially its flagship brand- MedCare Ozonated olive oil, primarily used for the treatment of acne, fungal infections, dry skin, insect bites, athlete’s foot, eczema, blisters, carbuncles, diabetic wounds, burns.

“We plan to enter the Indian market and will be soon formally launching our flagship product MedCare Ozonated olive oil,” Dermozone Chairman and CEO K S Dharshan said.

“We have invested over $4 million over a period of six years in developing MedCare Ozonated olive oil. We have done ample research that suggests a huge market for MedCare in India. Our anticipated revenues from this product alone would be in the region of $22 million in 3 years,” Dharshan added.

“We are also looking at the option of setting up a manufacturing base in India in the near future based on the ‘Make In India’ policy of the government. A final decision on this will be taken in the first quarter of 2016,” he further added.

Headquartered in Indonesia, Dermozone has its operations in UK, USA, Japan, Russia, Seoul and China.